Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Cancer Chemotherapy and Pharmacology|January 29, 2015
Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic diseaseEmily Chan, Eunice L Kwak, Jimmy Hwang, et al.
Cancer Investigation|April 7, 2015
A multicenter, open-label, Phase 1 study evaluating the safety and tolerability of pegaspargase in combination with gemcitabine in advanced metastatic solid tumors and lymphomaMitesh J Borad, Hani M Babiker, Stephen Anthony, et al.
Cancer Chemotherapy and Pharmacology|March 15, 2017
Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patientsD Mahadevan, Monica Mita, Donald Richards, et al.
Investigational New Drugs|February 5, 2013
A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumorsSunil Sharma, Joachim Beck, Monica Mita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumorsMuhammad Wasif Saif, Chris Takimoto, Monica Mita, et al.
Investigational New Drugs|February 18, 2011
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxelMichael Millward, Paul Mainwaring, Alain Mita, et al.
Investigational New Drugs|January 24, 2007
A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomasQuincy S C Chu, Bahram Forouzesh, Samira Syed, et al.
Cancer Chemotherapy and Pharmacology|October 12, 2012
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignanciesDa Zhang, Monica Mita, Geoffrey I Shapiro, et al.
Investigational New Drugs|February 15, 2017
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumorsMonica Mita, Siqing Fu, Sarina Anne Piha-Paul, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2008
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignanciesMonica Mita, Alain Mita, John Sarantopoulos, et al.
Pageof 6